4-(4-amino-2-fluorophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide | 1190837-13-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide
• CAS: 1190837-13-8
• 化学式: C₁₈H₁₆FN₃O₃
• 分子量: 341.342
• InChiKey: HKUDSAWEBILALG-UHFFFAOYSA-N

物化性质

• 沸点：
  565.3±50.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  86.5
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  异硫氰酸苯乙酰酯 、 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide 以 乙醇 、 甲苯 为溶剂， 以98.1 %的产率得到4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide
  参考文献：
  名称：

  US2023/107889

  摘要：

  公开号：
• 作为产物：
  描述：

  2-氟-4-硝基苯酚 在 5%-palladium/activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 、 甲醇 为溶剂， 反应 5.0h， 生成 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide
  参考文献：
  名称：

  QUINOLINE DERIVATIVE AND USE THEREOF

  摘要：

  提供了一种新型喹啉衍生物，或其药用可接受的盐、水合物，或其任何形式的代谢产物，以及其在制备用于预防和/或治疗与血管生成有关的适应症的药物中的用途。该喹啉衍生物是一种理想的高效VEGFR抑制剂，可用于治疗或预防与血管生成相关的肿瘤生长和其他转移性疾病的生长。

  公开号：

  US20190169163A1

文献信息

• ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE THEREOF
  申请人：Suda Yoshimitsu

  公开号：US20110034439A1

  公开（公告）日：2011-02-10

  To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed. The invention provides an acylthiourea compound represented by formula (I): (wherein each of R 1 and R 2 , which may be the same or different, represents a hydrogen atom, an optionally substituted C 1-6 alkyl group, an optionally substituted C 3-10 cycloalkyl group, an optionally substituted C 6-14 aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R 1 and R 2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R 3 represents a C 1-6 alkyl group; and each of R 4 , R 5 , and R 6 , which may be identical to or different from one another, represents a hydrogen atom, a halogen atom, an optionally substituted C 1-6 alkyl group, a C 1-6 alkoxy group, a C 1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R 5 and R 6 may form a ring together with the phenyl ring to which they are attached) or a salt thereof.

  提供一种抗肿瘤剂，其表现出优异的c-Met抑制作用，并通过选择性地影响c-Met特异表达的肿瘤细胞来减轻副作用。本发明提供一种由式(I)表示的酰基硫脲化合物：（其中，R1和R2中的每一个，可以相同也可以不同，表示氢原子，可选取代的C1-6烷基，可选取代的C3-10环烷基，可选取代的C6-14芳香烃基，或可选取代的饱和或不饱和杂环基，或R1和R2可以与它们所附着的氮原子一起形成一个可选取代的含氮杂环环；R3表示C1-6烷基；R4、R5和R6中的每一个，可以相同也可以不同，表示氢原子，卤素原子，可选取代的C1-6烷基，C1-6烷氧基，C1-6烷基氨基，可选取代的芳香烃基，或可选取代的饱和或不饱和杂环基，或R5和R6可以与它们所附着的苯环一起形成一个环）。或其盐。
• OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Wellmarker Bio Co., Ltd.

  公开号：EP4011885A1

  公开（公告）日：2022-06-15

  An oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines. Therefore, the oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention can be advantageously used for preventing or treating a disease associated with protein kinase activity.

  根据本发明，化学式1所代表的一种氧代吡啶融合环衍生物化合物或其药学上可接受的盐，可以有效抑制RON的活性，不仅可以有效抑制RON被激活的癌细胞系的细胞生长，还可以有效杀死癌细胞系。因此，根据本发明，化学式1所代表的氧代吡啶融合环衍生物化合物或其药学上可接受的盐可以有利地用于预防或治疗与蛋白激酶活性相关的疾病。
• Acylthiourea compound or salt thereof, and use thereof
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US08304427B2

  公开（公告）日：2012-11-06

  Provided is a c-Met inhibitory antitumor agent which mitigates side effects by selectively affecting tumor cells in which c-Met is specifically expressed, having a formula (I) or its salt: wherein each of R1 and R2 are independently a hydrogen atom, an optionally substituted C1-6 alkyl, C3-10 cycloalkyl, C6-14 aromatic hydrocarbon, or saturated or unsaturated heterocyclic group, or R1 and R2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R3 is a C1-6 alkyl group; and R4, R5, and R6, are independently a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R5 and R6 may form a ring together with the phenyl ring to which they are attached.

  提供一种c-Met抑制剂抗肿瘤剂，通过选择性地影响c-Met特异表达的肿瘤细胞来缓解副作用，其具有公式（I）或其盐： 其中，R1和R2分别独立地为氢原子、可选取代的C1-6烷基、C3-10环烷基、C6-14芳香烃或饱和或不饱和的杂环基，或R1和R2可以与它们连接的氮原子一起形成一个可选取代的含氮杂环环；R3是一个C1-6烷基；R4、R5和R6分别为氢原子、卤素原子、可选取代的C1-6烷基、C1-6烷氧基、C1-6烷基氨基、可选取代的芳香烃基或可选取代的饱和或不饱和杂环基，或R5和R6可以与它们连接的苯环一起形成一个环。
• ACYLTHIOUREA COMPOUND OR SALT THEREOF, AND USE OF THE COMPOUND OR THE SALT
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP2287155A1

  公开（公告）日：2011-02-23

  To provide an antitumor agent which exhibits excellent c-Met inhibitory effect and mitigates side effects by virtue of selectively affecting to tumor cells in which c-Met is specifically expressed. The invention provides an acylthiourea compound represented by formula (I): (wherein each of R1 and R2, which may be the same or different, represents a hydrogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C3-10 cycloalkyl group, an optionally substituted C6-14 aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R1 and R2 may form, together with the nitrogen atom to which they are attached, an optionally substituted nitrogen-containing heterocyclic ring; R3 represents a C1-6 alkyl group; and each of R4, R5, and R6, which may be identical to or different from one another, represents a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylamino group, an optionally substituted aromatic hydrocarbon group, or an optionally substituted saturated or unsaturated heterocyclic group, or R5 and R6 may form a ring together with the phenyl ring to which they are attached) or a salt thereof.

  提供一种抗肿瘤药，该抗肿瘤药对特异性表达 c-Met 的肿瘤细胞具有选择性影响，从而显示出卓越的 c-Met 抑制作用并减轻副作用。 本发明提供了一种由式（I）代表的酰基硫脲化合物： (其中 R1 和 R2（可以相同或不同）各自代表氢原子、任选取代的 C1-6 烷基、任选取代的 C3-10 环烷基、任选取代的 C6-14 芳烃基团或任选取代的饱和或不饱和杂环基团，或 R1 和 R2 可与所连接的氮原子一起形成任选取代的含氮杂环；R3代表C1-6烷基；R4、R5和R6（它们可以彼此相同或不同）分别代表氢原子、卤素原子、任选取代的C1-6烷基、C1-6烷氧基、C1-6烷氨基、任选取代的芳香烃基团或任选取代的饱和或不饱和杂环基团，或R5和R6可与它们所连接的苯基环一起形成环）或其盐。
• METHOD FOR PRODUCING ACYLTHIOUREA COMPOUND
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP4105200A1

  公开（公告）日：2022-12-21

  The present invention relates to a method for producing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide, the method comprising a step for linking 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide and 2-phenylacetyl isothiocyanate.

  本发明涉及一种生产4-(2-氟-4-(3-(2-苯乙酰基)硫脲基)苯氧基)-7-甲氧基-N-甲基喹啉-6-甲酰胺的方法，该方法包括将4-(4-氨基-2-氟苯氧基)-7-甲氧基-N-甲基喹啉-6-甲酰胺和2-苯乙酰基异硫氰酸酯连接起来的步骤。